Court Square Group

Court Square in action: Today Keith and Mary are in Miami- locked in the morning session of One-on-One Meetings at the Evolution Summit sharing the vision and value of Court Square.

meSummitsPharma on Twitter

Many of our clients are at the forefront of developing life-changing medicines for the future... This week we want to highlight BluebirdBio for their success with the new drug, LentiGlobin in treating TDT (Transfusion-Dependent β-Thalassemia) through gene therapy.
Individuals who have the genetic mutation causing TDT must undergo consistent blood transfusions to cope with the disease.
In this trial, observations stretch a two-year timeframe-- the collected data shows that the patients with TDT “were able to maintain independence from transfusion without unexpected or unmanageable side effects,” said Dr. Alexis Thompson, Head of Hematology and Director of the Comprehensive Thalassemia Program at Ann & Robert H. Lurie Children’s Hospital of Chicago, and Professor of Pediatrics at Northwestern University Feinberg School of Medicine and one of the lead authors of the NEJM paper.
She continued in her statement to the New England Journal of Medicine that, “These results suggest that gene therapy could become an effective treatment for TDT.”

Gene Therapy Looks Promising for Transfusion-Dependent β-Thalassemia